This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Diagnostic Marketing Association Names Cepheid 2011 Marketer Of The Year

Stock quotes in this article: CPHD

INDIANAPOLIS, May 1, 2012 /PRNewswire/ -- The Diagnostic Marketing Association ( DxMA), serving marketing, regulatory and medical affairs professionals in the diagnostic and device market segments, today presented its 2011 Marketer of the Year Award to Cepheid (Nasdaq: CPHD), a leading molecular diagnostics company. Presented at the annual DxMA Global Marketing Summit, the award recognizes innovation by marketers seeking to highlight their company and products at the leading edge of the diagnostic industry.

Cepheid was selected for its "Art Meets Innovation" campaign.  To unveil its redesigned GeneXpert® Systems at the 2011 American Association of Clinical Chemistry and Clinical Lab Expo, Cepheid partnered with Paul Jr. Designs, a world-renowned builder of custom motorcycles, to build a custom bike themed on its new GeneXpert Systems and molecular diagnostic testing. The live unveiling event was filmed for the popular Discovery Channel show American Chopper. The epic bike had to be "as cutting edge and innovative, yet as elegant as our technology," said Cepheid CEO John Bishop. An entire marketing campaign, including a road show with the bike, was developed around the 'Art Meets Innovation' theme.

"The Marketer of the Year Award is the highest accolade DxMA offers for diagnostic companies," said Robter Speziale, President DxMA. "It recognizes outstanding work that raises the bar in diagnostics marketing. In a crowded field, Cepheid stood out with its 'Art Meets Innovation' marketing campaign, by demonstrating the strongest commitment to marketing innovation, boldness and execution that symbolizes both Cepheid and its GeneXpert on-demand molecular testing technology."

To learn more about the Cepheid Bike and GeneXpert campaign, visit http://www.cepheid.com/cepheid-bike/.

About DxMA (Diagnostic Marketing Association)

The DxMA builds diagnostic industry leadership by providing knowledge and opportunities for professional development and the exchange of ideas. We serve marketing, regulatory compliance and medical affairs professionals who have devoted their careers to the diagnostics and device market segments. Members benefit from continued education and insight, networking with marketers from leading diagnostic companies and service providers, and the AACC seminar and DxMA Global Marketing Summit. For more information on the DxMA, visit www.dxma.org.

About Cepheid

Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs